Salvans™ Active Ingredient Against Naso-Oropharyngeal Bacterial Infections
Acute pharyngitis/tonsillitis is characterized by inflammation of the posterior pharynx and tonsils. Most of these infections are caused by viruses, but in 5 - 37% of these cases group A streptococci (GAS), and of these almost always the bacterium Streptococcus pyogenes is responsible. These bacterial pharyngeal infections occur more frequently in children than in adults.
Acute Streptococcus pyogenes pharyngitis is often a self-limiting disease, and antibiotics reduce the duration of symptoms on average by one day only. In addition, contemporary treatment guidelines recommend verifying Streptococcus colonization by throat swab cultures before prescribing antibiotics, so that treatment often is significantly delayed until they are no longer needed. The clinical symptoms of pharyngitis are most commonly treated unspecifically by local analgetics and pain medication.
Streptococcus pyogenes infections, especially in children, can lead to post-infection complications with significant morbidity including infections of superficial or deep layers of the skin, heart valve infection, induction of autoimmune disease including rhematic fever or nephritis, and neuroinflammatory diseases like PANS/ PANDAS.
16% of children are long-term carriers of Streptococcus pyogenes without acute pharyngitis. Children who are Streptococcus pyogenes carriers are more likely to develop neurologic symptoms with rapid onset, such as motor or vocal tics and behavioral findings like irritability, aggressive behavior, anxiety attacks, extreme mood swings as well as problems with school subjects such as math and reading.
There is a high unmet medical need for low-threshold non-antibiotic prophylactic and therapeutic approaches against Streptococcus pyogenes, that do not require extensive microbiologic testing and multiple visits at a general practicioner until prescription. A low threshold OTC product can help significantly reducing the morbidity burden induced by often untreated upper respiratory Streptococcus pyogenes colonization.
The active ingredient Salvans™, which is based on a highly selected Lactobacillus crispatus strain, has been identified as an innovative anti-Streptococcus pyogenes active in a complex screening procedure from a large bacterial strain collection. Salvans™ consists of inactivated, freeze-dried Lactobaclillus crispatus cells in a starch matrix and is patent protected.
The Mechanism Of Action Of Salvans™
The effect of the Salvans™ bacterium on Streptococcus pyogenes is fascinating. Within milliseconds, Streptococcus pyogenes firmly adheres to the cell walls of inactivated Salvans™ bacteria and co-aggregates when brought together in a liquid environment. Lumps of these co-aggregates can be observed under the electron microscope. These co-aggregates can be mechanically removed from the throat by saliva flow. This effect is highly selective, the active ingredient does not aggregate with commensal oral bacteria. Thus Salvans™ has no adverse effects on the human oral microbiome.
Since the mechanism of action is based on the bacterial cell wall, we do not need to introduce living bacteria in products. Salvans™ contains only the bacterial envelopes and does not impose any risks of overcolonization or genetic transfer with the oral microbiome.
It is intended to develop prophylactic substance-based medical device products against naso-oropharyngeal Streptococcus pyogenes colonization based on the active ingredient Salvans™.
Based on a significant amount of in vitro evidence regarding the innovative mode of action we are interested in cooperating with interested partners in substance-based medical device product development and commercialization in the area of OTC oral care and/or cold remedies.
Salvans™ is patent protected.